Gyala Therapeutics is conducting a Phase I/IIa clinical trial to evaluate the safety of GYA01, an investigational CD84-targeted CAR-T cell therapy, in patients with relapsed or refractory acute myeloid leukemia (AML) and acute lymphoblastic T leukemia (T-ALL).
The study enrolls patients with limited or no remaining therapeutic options and is being conducted at two reference hematology centers in Spain: Hospital La Fe in Valencia and Hospital Clínic Barcelona.
For complete and authoritative information on study design, eligibility criteria, recruitment status, and site-specific contacts, please consult the official clinical trial registries:
ClinicalTrials.gov:
Spanish Clinical Trials Registry (REec): https://reec.aemps.es/reec/estudio/2024-519966-31-00